China Medical System Holdings Limited said on Oct, 27 2025 that its subsidiaries have entered into an exclusive five-year Distribution Agreement with Novartis Pharma Services AG covering Ranibizumab Injection (Lucentis) and Brolucizumab Injection (Beovu) in mainland China.
Under the deal, Novartis will continue to manufacture and supply both ophthalmic drugs, while the Group will be responsible for their importation, distribution, sales and agreed promotion activities across the territory, which excludes Hong Kong, Macau and Taiwan.
Lucentis, first approved in China in 2011, targets vascular endothelial growth factor A and is indicated for multiple ocular neovascular diseases, including neovascular age-related macular degeneration and diabetic macular edema. Beovu, approved by China’s National Medical Products Administration in May 2025 for diabetic macular edema, is a next-generation anti-VEGF therapy designed for longer dosing intervals.
The company said adding Lucentis and Beovu will complement its existing ophthalmology portfolio—such as Augentropfen Stulln Mono Eye Drops and the EyeOP1 Glaucoma Treatment Device—and is expected to strengthen its academic presence and improve operational efficiency within its CMS Vision unit.
China Medical System stated that all applicable percentage ratios for the transaction are below 5%, so it is not a notifiable or connected transaction under Hong Kong listing rules. The announcement was made on a voluntary basis, and the company advised shareholders and investors to exercise caution when dealing in its securities.
Comments